πŸ‡ΊπŸ‡Έ FDA
Patent

US 9675663

TUSC2 therapies

granted A61KA61K2039/505A61K31/517

Quick answer

US patent 9675663 (TUSC2 therapies) held by The Board of Regents of the University of Texas System expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K31/517, A61K31/7088, A61K31/7135